Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;55(9):1865-1867.
doi: 10.1038/s41409-020-0844-2. Epub 2020 Feb 26.

Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma

Katia Mancuso  1 , Paola Tacchetti  1 , Lucia Pantani  1 , Serena Rocchi  1 , Ilaria Rizzello  1 , Isola Caratozzolo  1 , Gabriella De Cicco  1 , Alessio Fusco  1 , Nicoletta Testoni  1 , Carolina Terragna  1 , Giulia Marzocchi  1 , Marina Martello  1 , Enrica Borsi  1 , Luca Dozza  1 , Michele Cavo  2 , Elena Zamagni  1
Affiliations

Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma

Katia Mancuso et al. Bone Marrow Transplant. 2020 Sep.
No abstract available

PubMed Disclaimer

References

    1. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89. - DOI
    1. Jackson G, Davies FE, Pawlyn C, Cairns DA, Striha A, Collettet C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73. - DOI
    1. Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegmanet S, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2017;32:383–90. - DOI
    1. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119:940–8. - DOI
    1. Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulosm S, Kang Y, et al. Outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transpl. 2017;23:262–8. - DOI

MeSH terms

LinkOut - more resources